Andrea Tummins
Psychiatric/Mental Health · Dickson, TNNPI 1669642518
Payments from drug & device makers
Across 115 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$509
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$302
- Neurocrine Biosciences, Inc.$282
- E.r. Squibb & Sons, L.L.C.$274
- Sunovion Pharmaceuticals Inc.$261
- AbbVie$251
- plus $914 from 12 others
What the payments were for
- Food & beverage$2,76499%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 4 | $509 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $302 |
| Neurocrine Biosciences, Inc. | 12 | $282 |
| E.r. Squibb & Sons, L.L.C. | 10 | $274 |
| Sunovion Pharmaceuticals Inc. | 15 | $261 |
| AbbVie | 16 | $251 |
| Otsuka America Pharmaceutical, Inc. | 11 | $226 |
| Axsome Therapeutics, Inc. | 10 | $203 |
| Johnson & Johnson | 7 | $133 |
| Alkermes, Inc. | 4 | $88 |
| Teva Pharmaceuticals USA, Inc. | 4 | $79 |
| Indivior Inc. | 3 | $44 |
| Lundbeck LLC | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
| Boston Scientific | 1 | $14 |
| Merck | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$457
How this compares
$2,792 in reported general payments places this provider in the 75th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 75 | $230,774 |
| AustedoDeutetrabenazine | 12 | $129,150 |
| VraylarCariprazine Hcl | 67 | $109,045 |
| Invega TrinzaPaliperidone Palmitate | 12 | $99,578 |
| Abilify MaintenaAripiprazole | 34 | $84,628 |
| RexultiBrexpiprazole | 52 | $80,811 |
| Risperdal ConstaRisperidone Microspheres | 23 | $52,733 |
| PerserisRisperidone | 14 | $36,568 |
| TrintellixVortioxetine Hydrobromide | 47 | $24,345 |
| Aripiprazole | 327 | $23,539 |
| CaplytaLumateperone Tosylate | 14 | $22,480 |
| AuvelityDextromethorphan Hbr/Bupropion | 16 | $22,193 |
| Lurasidone Hcl | 92 | $13,007 |
| Paliperidone ErPaliperidone | 65 | $10,307 |
| Olanzapine | 269 | $7,503 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $133 | $383,085110 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $226 | $165,43986 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $79 | $129,15012 claims |
| AbbVieVraylar | $251 | $109,04567 claims |
| Indivior Inc.Perseris | $44 | $36,56814 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $38 | $24,34547 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $302 | $22,48014 claims |
| Axsome Therapeutics, Inc.Auvelity | $203 | $22,19316 claims |
| MerckBelsomra | $14 | $6,69115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Dickson
- Deandra SmithDickson$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
- Mary AllenMemphis$422K
- Lauren HansenNashville$263K
- Joshua ThompsonChattanooga$262K
- Kristal HurstBlaine$260K
- Kaitlynn EarlsGreeneville$228K
- Tory WoodardCookeville$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.